EHA Preview | CARsgen to Present Results of Zevorcabtagene Autoleucel and CT071 at 2024 EHA

CARsgen Submitted Responses to FDA Observations

ASCO Preview | CARsgen to Present Results of CT041 at 2024 ASCO

CARsgen Announced 2023 Annual Results

NMPA Approves the NDA for CARsgen's BCMA CAR-T Therapy Zevorcabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

CARsgen’s Presents Updated Research Results on CT041 at 2024 ASCO GI Meeting

CARsgen’s CT011 achieves IND clearance from the NMPA for the GPC3-positive stage Ⅲa hepatocellular carcinoma at high risk of recurrence after surgical resection

CARsgen Presents Updated Research Results on Zevor-cel at 2023 ASH Annual Meeting

CARsgen’s CT071 Received IND Clearance from the FDA for Treating Relapsed/Refractory Multiple Myeloma or Relapsed/Refractory Primary Plasma Cell Leukemia

CARsgen Announces Formation of its Clinical Advisory Board